SUNRISE, Fla., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB), a company focused on developing stem cell therapies for heart disease announced that they have entered into an agreement with Stemlogix, LLC, a veterinary regenerative medicine company, to provide additional cellular products and services to the veterinary market. Under the agreement, the companies will offer culture expanded bone marrow and adipose stem cells for use in animals with degenerative diseases or acute injuries. In addition, veterinary patients will have the option to bank their stem cells for future use.
